These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 7621458)
1. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Oliver RT; Gallagher CJ Cancer Surv; 1995; 23():191-207. PubMed ID: 7621458 [TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
5. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer]. Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583 [TBL] [Abstract][Full Text] [Related]
6. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches. Hoffmann J; Sommer A J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262 [TBL] [Abstract][Full Text] [Related]
7. Intermediate biomarkers for chemoprevention of prostate cancer. van der Kwast TH IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659 [TBL] [Abstract][Full Text] [Related]
8. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332 [TBL] [Abstract][Full Text] [Related]
9. [Adenocarcinoma of the prostate]. Dvorácek J Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503 [TBL] [Abstract][Full Text] [Related]
10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
11. [First line therapy in the treatment of metastatic prostate cancer]. Sakai H; Kanetake H Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704 [TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy for prostate cancer. Damber JE Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920 [TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
15. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414 [TBL] [Abstract][Full Text] [Related]
16. Standard treatments induce antigen-specific immune responses in prostate cancer. Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294 [TBL] [Abstract][Full Text] [Related]